Subjects wore a therapeutic or sham device prior to the usual onset of symptoms for a minimum of 1 h daily. Measures of severity of illness, quality of life, daytime sleepiness, and fatigue were ...

Results: Device users reported overall reduction in pain at two hours at -65 mm on the VAS, compared with -9 mm for the sham users. Thirty patients, or 76.92 percent of the sham group, needed ...

After a while, the same level of pain was applied, but this time with the sham device turned on. Those who experienced more pain under these conditions were considered more sensitive to the nocebo ...

Of the 164 patients who treated a migraine attack, 39% of patients who used the sTMS device reported they were pain free after 2 h, compared with only 22% of patients who received sham stimulation.

Cardiac Dimensions has completed four trials that investigated the devices’ safety and performance, with the fourth conducted as a fully randomized, blinded, sham-controlled trial of patients.

The study devices and matching sham devices were provided by Aircast LLC (Summit, NJ). Aircast was not involved in the design or completion of the study, nor in the preparation of this article.